Recent advances in specific signalling pathways of cancer cells have introduced targeted therapy into treatment regimes for patients with metastatic colorectal cancer (CRC) ([@bib29]). Cetuximab and panitumumab are monoclonal antibodies that bind to the extracellular domain of the epidermal growth factor receptor (EGFR). They inhibit ligand-induced stimulation of several intracellular signalling pathways, such as RAS/RAF/MAPK and phosphoinositide-3 pathway, which results in decreased stimulation of cell cycle progression, proliferation, angiogenesis, and stimulation of apoptosis ([@bib24]). The *KRAS* oncogene is currently the most relevant molecular biomarker that predicts the response to EGFR-targeted therapy in CRC. An oncogenic mutation in *KRAS* leads to constitutive activation of the RAS/RAF signalling pathway independent from EGFR activation by binding of the ligand ([@bib7]). *KRAS* mutations occur in approximately 38% of colorectal tumours and involve codon 12 and 13 in \>96% of cases ([@bib20]). Metastatic CRC patients with tumours harbouring a *KRAS* mutation are resistant to treatment with anti-EGFR antibodies, showing lower response rates, decreased progression-free survival, and overall survival compared with patients with *KRAS* wild-type tumours ([@bib14]; [@bib28]; [@bib30]). Therefore, the European Medicines Agency and the Food and Drug Administration have restricted the use of anti-EGFR antibodies in metastatic CRC to patients with *KRAS* wild-type tumours.

Cetuximab and panitumumab have shown efficacy both as monotherapy ([@bib3]; [@bib14]) and in combination with chemotherapy ([@bib28]; [@bib30]) in patients with *KRAS* wild-type metastatic CRC. Nevertheless, even among patients with *KRAS* wild-type tumours, the majority of patients do not respond to anti-EGFR therapy. Efficacy of anti-EGFR therapy was suggested to be further restricted to patients with *BRAF* wild-type tumours ([@bib10]). An additional explanation for the suboptimal response rates to anti-EGFR antibodies in patients with *KRAS* wild-type tumours is discordance of *KRAS* mutation status between primary colorectal tumours and corresponding metastases. In the early dissemination model, tumour cells depart the primary lesion before the acquisition of a fully malignant phenotype to undergo new mutations and metastatic growth at a distant site ([@bib15]). According to this model, a discordance in mutation status between primary tumours and metastases may occur, and as a consequence the mutation status of the primary tumour might not be adequate to predict the response of metastases to anti-EGFR treatment.

Current data on the concordance in *KRAS* mutation status between primary colorectal tumours and metastases are conflicting. Five studies showed a 100% concordance of *KRAS* mutation status in primary CRC and corresponding metastases ([@bib16]; [@bib26]; [@bib33]; [@bib32]; [@bib11]). In contrast to these data, others have reported a discordance of *KRAS* mutation status in primary tumours and metastatic sites, with an overall discordance observed in 4--32% of the patients ([@bib21]; [@bib1]; [@bib2]; [@bib19]; [@bib4]; [@bib23]; [@bib8]; [@bib12]; [@bib17]; [@bib18]; [@bib22]; [@bib5]; [@bib13]). These controversial results are probably due to the fact that these studies were underpowered with a small number of patients, and included a wide variety of metastatic sites. Therefore, it is still uncertain whether the evaluation of *KRAS* mutation status in the most commonly available primary tumour correctly reflects the *KRAS* mutation status of corresponding metastasis. This is highly relevant given the large number of CRC patients as well as the potential toxicity and costs of anti-EGFR therapy.

We assessed the concordance in *KRAS* mutation status in primary tumours and their corresponding liver metastases in an adequately powered study of 305 CRC patients.

Patients and methods
====================

Patient selection
-----------------

Patients with histologically confirmed CRC who underwent surgical resection of the primary tumour and biopsy or surgical resection of the corresponding liver metastasis were included in this analysis. Results were obtained from archived material of three large pathology laboratories and from material collected from the CAIRO2 study, a large multicentre trial of the Dutch Colorectal Cancer Group ([@bib28]).

In patients with a discordance of *KRAS* mutation status between the primary tumour and metastasis, additional blocks of the primary tumour were obtained to exclude heterogeneity within the tumour. Lymph node metastases present at the time of diagnosis were also acquired in these patients.

Tumour DNA preparation
----------------------

Formalin-fixed paraffin-embedded tissue blocks were cut at 4 *μ*m thickness and stained with haematoxylin and eosin (HE). The presence of tumour tissue was marked by a pathologist. Subsequently the blocks were cut at 20--40 *μ*m thickness and micro dissected for DNA extraction. Tumour tissue was dissolved in 200 *μ*l lysis buffer (QIAamp DNA Micro Kit, Qiagen, Venlo, The Netherlands) and incubated with proteinase K overnight at 56 °C for two nights. DNA was extracted according to the manufacturer\'s protocol (QIAamp DNA Micro Kit, Qiagen), and DNA concentration was determined at 260 nm using the Nanodrop 26 ND-1000 spectrophotometer (Nanodrop Technologies Inc., Wilmington, NC, USA).

*KRAS* mutation analysis
------------------------

For *KRAS* mutation analysis, exon 2 (codon 12 and 13) was amplified using a 50 *μ*l reaction mixture containing 0.2 *μ*m forward (5′-TGTAAAACGACGGCCAGTAGGCCTGCTGAAAATGACTG-3′) and reverse (5′-CAGGAAACAGCTATGACCTGGATCATATTCGTCCACAAAA-3′) primers (Invitrogen, Breda, The Netherlands); dATP, dCTP, dGTP and dTTP (GE Healthcare, Zeist, The Netherlands) at 0.2 m each; 50 m KCl; 10 m Tris-HCl (pH 8.3); 2.5 m MgCl~2~; 1 U AmpliTaq Gold polymerase (Applied Biosystems, Nieuwkerk a/d IJsel, The Netherlands) and 50 ng of template DNA. The PCR conditions were as follows: 94 °C for 10 min; 92 °C for 1 min, 60 °C for 1 min, 72 °C for 1 min (40 cycles); and 72 °C for 10 min.

All PCR products were purified with the MultiScreen HTS, 96 well Filtration System (Millipore, Carrigtwohill, Ireland). Subsequently, the purified products were sequenced using fluorescently labelled terminators (BigDye Terminators (v 1.1); Applied Biosystems, Foster City, CA, USA) with both M13-forward and M13-reverse sequencing primers. The sequencing products were analysed on an ABI 3730 DNA Analyser (Applied Biosystems) and the data analysis was performed using Sequencing Analysis Software Sequencing Analysis Software v5.3.1 with KBTM Basecaller. Sequence results were scored by visual inspection of the chromatograms (Applied Biosystems).

Statistical analysis
--------------------

We considered a discordance level of 5% or more to be clinically relevant, that is, leading to substantial change in routine clinical practice. To exclude such level of discordance under the assumption that the true discordance was 2.5% or less, we set the sample size at 304 paired samples. With this sample size, the precision in the estimated percentage of discordance was 2.5% (i.e., s.e. 1.25, half-width of the 95% confidence interval equal to 2.5%).

The comparison of patient and primary tumour characteristics between patients with *KRAS* wild-type and *KRAS* mutant primary tumours was done using Wilcoxon\'s rank sum test or *χ*^2^ for numerical or categorical variables, respectively. Differences in *KRAS* mutation status between the primary tumour and corresponding metastasis were analysed by calculating the percentage of concordance, and (clinically relevant) discordance, together with the corresponding Clopper--Pearson 95% confidence intervals. Differences were considered to be statistically significant when the *P*-value was below 0.05. All statistical tests were two-sided.

Results
=======

Patient characteristics
-----------------------

We analysed *KRAS* codon 12 and 13 mutations in 320 matched primary colorectal tumours and liver metastases. The tumour cell percentages in all primary tumours and metastases were above 30%. We failed to obtain a *KRAS* mutation status in 15 patients; therefore our further analyses were performed in 305 paired samples. Patient characteristics are shown in [Table 1](#tbl1){ref-type="table"}.

*KRAS* mutation and histopathological parameters
------------------------------------------------

A total of 108 patients (35.4%) had a *KRAS* mutation in the primary tumour; of which 37 patients had a Gly12Asp mutation, 28 patients a Gly12Val mutation, 14 patients a Gly13Asp mutation, 10 patients a Gly12Cys mutation, 7 patients a Gly12Ser mutation, 7 patients a Gly12Ala mutation, 3 patients a Gly12Arg mutation, 1 patient a Gly12Asp and Gly12Ala mutation and 1 patient a Gly12Phe mutation ([Table 2](#tbl2){ref-type="table"}). Histopathological characteristics of the primary tumour were comparable between patients with and without a *KRAS* mutation ([Table 1](#tbl1){ref-type="table"}).

Concordance of *KRAS* status in primary tumours and corresponding liver metastases
----------------------------------------------------------------------------------

In 294 patients (96.4% 95% CI 93.6--98.2%), the same *KRAS* mutation status was obtained from the primary tumour and the corresponding liver metastasis. In 11 patients (3.6% 95% CI 1.8--6.4%), of which 7 had synchronous metastases at diagnosis and 4 developed metachronous metastases, we found a discordance between primary tumours and metastases. Five patients had a *KRAS* mutation in the primary tumour and not in the liver metastasis. Only one patient had a wild-type status of the primary tumour, while the metastasis showed a *KRAS* mutation. In five patients, the primary tumours had different *KRAS* mutations compared with the metastases. One of these patients had two primary tumours. Both primary tumours had the same *KRAS* mutation (Gly13Asp), while the liver metastasis had a different *KRAS* mutation (Gly12Ser). In another patient, the primary tumour had a double mutation (Gly12Asp/Gly12Val) and the metastasis had a Gly12Asp mutation ([Figure 1](#fig1){ref-type="fig"}, [Table 3](#tbl3){ref-type="table"}). Taken together, the observed discordance was clinically relevant in only six patients (2.0% 95% CI 0.7--4.2%).

Subsequent analyses in patients with a discordance of *KRAS* status
-------------------------------------------------------------------

Several tests were performed to exclude bias of the test results. First, the HE coupes of all patients with a discordant *KRAS* mutation status between the primary tumour and liver metastasis were revised. The primary tumours and liver metastases had a mean tumour cell percentage of 65 and 60%, respectively. Subsequent independent reanalysis of the *KRAS* mutation status resulted in the same discordances.

Second, several mutation analyses were performed on different areas of the tumour and from different tumour blocks in order to establish possible tumour heterogeneity. Two patients showed heterogeneity of *KRAS* status within the primary tumour. One of these patients demonstrated two areas with a Gly12Asp mutation and one area with wild-type status, of which the latter resembled the liver metastasis. The other patient showed two different *KRAS* mutations within the same tumour, of which one is concordant with the liver metastasis ([Table 3](#tbl3){ref-type="table"}).

Third, 6 of the 11 patients with discordant results did have lymph nodes metastases at the time of diagnosis. *KRAS* mutation testing of all lymph nodes separately revealed overall concordant *KRAS* status between lymph node metastases and the primary tumour in three patients. The *KRAS* status of the lymph nodes in the other three patients showed heterogeneity, of which at least one lymph node metastases showed a different *KRAS* status compared with the primary tumour. However, this explains the discordance between the primary tumour and liver metastasis only in one patient ([Table 3](#tbl3){ref-type="table"}).

Discussion
==========

This is the first adequately powered study in CRC that compares *KRAS* mutation status between primary tumours and their corresponding liver metastases. We showed that tissue from the primary tumour can reliably be used for *KRAS* mutation testing in order to select patients for anti-EGFR therapy.

We observed a concordant *KRAS* mutation status in 96.4% of 305 paired samples of colorectal tumours and liver metastases. However, the difference in *KRAS* status was not clinically relevant in 5 of the 11 patients with discordant results, because both primary tumour and metastasis had a different *KRAS* mutation. Given the high statistical power of our analysis, we were able to obtain a highly accurate estimate of the level of discordance that enabled us to conclude that the level of discordance was 2.0%. The high rate of concordance is in agreement with the notion that *KRAS* mutations are considered as early driving events in CRC progression, and associated with the growth of small adenoma to clinically significant size ([@bib31]). Therefore, *KRAS* mutation status is expected to be equal in both primary tumours and metastases ([@bib15]).

The previously reported lower concordance levels between primary tumours and metastases are most likely due to bias caused by false-negative results in underpowered studies. We calculated that 304 paired cases were needed to reliably exclude a rate of discordance of \>5%, while previous studies included only 10 to 110 patients ([Table 4](#tbl4){ref-type="table"}). Moreover, in these studies metastases of different sites were compared with the primary tumour. As the molecular patterns may differ between metastatic sites ([@bib15]), more reliable results are obtained when *KRAS* mutation status is tested more rigorously for each metastatic site. The liver is the predominant site of metastases in the majority of metastatic CRC patients; therefore the results of our large series of 305 liver metastases provide a solid reference for clinical decision making as to anti-EGFR therapy. Another issue is the fact that *KRAS* testing is technically not as straightforward as is often assumed. Several quality assurance systems are now in place, and the first 'round robin\' test indicates that at least 30% of the experienced pathology laboratories fail to pass the threshold level of the quality assurance programs ([@bib6]). Other important facts about *KRAS* testing are the correct evaluation of the amount of tumour tissue in the sample and the sensitivity of testing methods. In a previous study, we demonstrated in \>500 samples that both sequencing and real-time PCR are reliable methods ([@bib27]).

A discordant *KRAS* status between the primary tumour and metastasis was observed in a small number of patients (3.6%). In these cases, tumour cells may have departed the primary lesions before the acquisition of a fully malignant phenotype to undergo somatic mutations or deletions at a distant site ([@bib15]). Another explanation for the discordant results may be heterogeneity of *KRAS* status within the primary tumour, although this was the case in only a small number of patients. Finally, a discordance may in theory be explained by metastases from a non-detected second primary.

Previously published data showed that a considerable fraction (25%, [Table 4](#tbl4){ref-type="table"}) of colorectal lymph node metastases does not resemble the primary tumour in terms of *KRAS* mutation status. In 5 of the 25 lymph node metastases that we tested the *KRAS* status was not concordant with the primary tumour, which is consistent with the literature ([Table 4](#tbl4){ref-type="table"}). Therefore, lymph node metastases do not seem suitable for determination of the *KRAS* mutation status of colorectal carcinomas. Discordance in *KRAS* mutation status might be due to clonal selection during the process of metastasis, however, heterogeneity in lymph node metastases could explain this discordance in only one patient.

Eight different *KRAS* mutation types were observed in our study, of which Gly12Asp showed the highest frequency. Five patients (1.6%) harboured different *KRAS* mutation types in the primary tumour compared with the metastases. This confirms the findings of [@bib8] and [@bib2], who reported a small number of patients (4 and 7%, respectively) with different mutation types between primary tumours and metastases. A different *KRAS* mutation type between primary lung adenocarcinomas and corresponding lymph node metastases was also observed in only 1% of the patients ([@bib25]). Currently, all patients with a *KRAS* mutation are excluded from treatment with anti-EGFR antibodies, independently of the mutation type. However, a recent paper indicated that codon 13 mutated tumours may be sensitive to cetuximab treatment ([@bib9]). As we observed a low frequency in *KRAS* mutation type discrepancies between primaries and metastases, this is not of clinical importance in selecting patients for anti-EGFR therapy.

In conclusion, we demonstrated a high level of concordance of 96.4% between primary tumours and liver metastases, which for clinical purposes to select CRC patients for anti-EGFR therapy was even higher with 98%. The implication of these results for general oncology practice is that both tissue of primary tumour or liver metastasis may be used for *KRAS* mutation testing. The results of our study are only valid for liver metastases and cannot be extrapolated to other metastatic locations. Furthermore, we demonstrated that discordance of test results between primary tumour and metastases cannot account for the failure rate of anti-EGFR therapy in patients with *KRAS* wild-type tumours. Therefore, novel predictive markers in addition to *KRAS* and *BRAF* mutation status are warranted.

This study was supported by a grant of the Dutch Colorectal Cancer Group (DCCG).
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###### Distribution of tumour characteristics according to *KRAS* status of the primary tumour

                                        **Overall, *n*=305**   ***KRAS* mutation, *n*=108**   ***KRAS* wild type, *n*=197**   ***P*-value**
  ------------------------------------- ---------------------- ------------------------------ ------------------------------- ---------------
  *Age*                                 0.20                                                                                  
   Median (IQR)                         64 (57--70)            65 (58--71)                    64 (57--70)                      
  *Gender*                              0.37                                                                                  
   Male                                 191 (62.6%)            64 (59.3%)                     127 (64.5%)                      
   Female                               114 (37.4%)            44 (40.7%)                     70 (35.5%)                       
  *Metastases presentation*             0.45                                                                                  
   Synchronous                          169 (55.4%)            63 (58.3%)                     106 (53.8%)                      
   Metachronous                         136 (44.6%)            45 (41.7%)                     91 (46.2%)                       
  *Tumour location*                     0.63                                                                                  
   Colon                                167 (54.8%)            59 (54.6%)                     108 (54.8%)                      
   Rectum                               54 (17.7%)             16 (14.8%)                     38 (19.3%)                       
   Rectosigmoid                         80 (26.2%)             32 (29.6%)                     48 (24.4%)                       
   Unknown                              4 (1.3%)               1 (0.9%)                       3 (1.5%)                         
  *Histopathological subtype*           0.12                                                                                  
   Adenocarcinoma                       271 (88.9%)            90 (83.3%)                     181 (91.9%)                      
   Adenocarcinoma with muc. component   21 (6.9%)              10 (9.3%)                      11 (5.6%)                        
   Mucinous adenocarcinoma              8 (2.6%)               5 (4.6%)                       3 (1.5%)                         
   Unknown                              5 (1.6%)               3 (2.8%)                       2 (1.0%)                         
  *Differentiation grade*               0.21                                                                                  
   Good                                 33 (10.8%)             13 (12.0%)                     20 (10.2%)                       
   Moderate                             196 (64.3%)            65 (60.2%)                     131 (66.5%)                      
   Poor                                 52 (17.0%)             17 (15.7%)                     35 (17.8%)                       
   Unknown                              24 (7.9%)              13 (12.0%)                     11 (5.6%)                        
  *T stage*                             0.62                                                                                  
   T1                                   4 (1.3%)               2 (1.9%)                       2 (1.0%)                         
   T2                                   20 (6.6%)              9 (8.3%)                       11 (5.6%)                        
   T3                                   231 (75.7%)            81 (75.0%)                     150 (76.1%)                      
   T4                                   36 (11.8%)             11 (10.2%)                     25 (12.7%)                       
   Unknown                              14 (4.6%)              5 (4.6%)                       9 (4.6%)                         
  *N stage*                             0.10                                                                                  
   N0                                   114 (37.4%)            46 (42.6%)                     68 (34.5%)                       
   N1                                   87 (28.5%)             31 (28.7%)                     56 (28.4%)                       
   N2                                   86 (28.2%)             26 (24.1%)                     60 (30.5%)                       
   Unknown                              18 (5.9%)              5 (4.6%)                       13 (6.6%)                        
  *Number of lymph nodes examined*      0.28                                                                                  
   Median (IQR)                         10 (6--15)             10 (6--13)                     10 (6--16)                       
  *Number of lymph node metastases*     0.15                                                                                  
   Median (IQR)                         1 (0--4)               1 (0--3)                       1 (0--4)                         

Abbreviation: IQR=interquartile range.

###### Distribution of *KRAS* mutation types

  **Codon 12/13**       **Patients with *KRAS* mutation (*n*, **%**)**
  --------------------- ------------------------------------------------
  Gly12Asp              37 (34%)
  Gly12Val              28 (26%)
  Gly13Asp              14 (13%)
  Gly12Cys              10 (9%)
  Gly12Ser              7 (6%)
  Gly12Ala              7 (6%)
  Gly12Arg              3 (3%)
  Gly12Phe              1 (1%)
  Gly12Asp + Gly12Ala   1 (1%)

###### Patients with a discordant *KRAS* status between primary tumour and liver metastasis. Multiple blocks of primary tumour tissue and lymph node metastases were tested when available

       ***KRAS* status primary tumour**    ***KRAS* status 2nd tumour**  ***KRAS* status lymph node metastasis**   ***KRAS* status liver metastasis**
  ---- ---------------------------------- ------------------------------ ----------------------------------------- ------------------------------------
  1    Gly12Ala                                        ---               LN 1: Gly12Ala                            WT
                                                                         LN 2: Gly12Ala                             
                                                                         LN 3: Gly12Ala                             
  2    Gly12Asp                                        ---               ---                                       WT
       Gly12Asp                                                                                                     
       WT                                                                                                           
  3    Gly12Cys                                        ---               ---                                       WT
  4    Gly12Asp                                        ---               LN 1: Gly12Asp                            WT
       Gly12Asp                                                          LN 2: Gly12Asp                             
       Gly12Asp                                                          LN 3: Gly12Asp                             
       Gly12Asp                                                          LN 4: Gly12Asp                             
                                                                         LN 5: WT                                   
  5    Gly12Ser                                        ---               ---                                       WT
  6    WT                                              ---               ---                                       Gly12Cys
  7    Gly12Asp                                        ---               LN 1: WT                                  Gly12Ala
                                                                         LN 2: WT                                   
                                                                         LN 3: WT                                   
  8    Gly13Asp                                      Gly13Asp            LN 1: Gly13Asp                            Gly12Ser
  9    Gly12Ser                                        ---               ---                                       Gly12Ala
  10   Gly12Cys                                        ---               LN 1: Gly12Asp                            Gly12Asp
       Gly12Asp                                                          LN 2: Gly12Asp                             
                                                                         LN 3: Gly12Asp                             
                                                                         LN 4: Gly12Asp                             
                                                                         LN 5: Gly12Asp                             
                                                                         LN 6: WT                                   
  11   Gly12Asp/Gly12Val                               ---               LN 1: Gly12Val                            Gly12Asp
                                                                         LN 2: Gly12Val                             
                                                                         LN 3: Gly12Val                             
                                                                         LN 4: Gly12Asp                             
                                                                         LN 5: Gly12Asp                             
                                                                         LN 6: Gly12Asp                             
                                                                         LN 7: Gly12Asp                             

Abbreviation: WT=wild type.

###### Overview of studies providing data on *KRAS* status of primary tumour and related metastasis

  **Author study**    **Year**  **No. of pts**   **Analysed metastatic site**        **Method**                ***KRAS* mutation in PT (%)**   ***KRAS* mutation in PT, WT in M**   ***KRAS* WT in PT, mutation in M**   **Total percentage of discordance**
  ------------------ ---------- ---------------- ----------------------------------- ------------------------ ------------------------------- ------------------------------------ ------------------------------------ -------------------------------------
  Albanase              2004    30               Liver                               SSCP analysis                       14 (47%)                          5/14 (36%)                           4/16 (25%)                           9/30 (30%)
  Al-Mulla              1998    26               Liver                               ASO/direct seq                      10 (38%)                          2/10 (20%)                           3/16 (19%)                           5/26 (19%)
                                31               Lymph node                          ASO/direct seq                      10 (32%)                          1/10 (10%)                           5/21 (24%)                           6/31 (19%)
  Artale                2008    48               Diverse, 81% liver                  Direct seq                          11 (23%)                          1/11 (9%)                            2/37 (5%)                             3/48 (6%)
  Baldus                2010    20               Visceral metastasis                 Direct seq                           9 (45%)                          1/9 (11%)                            1/11 (9%)                            2/20 (10%)
                                55               Lymph node                          Direct seq                          29 (53%)                         15/29 (52%)                           2/26 (8%)                            17/55 (31%)
  Cejas                 2010    93               Liver                               Direct seq                          30 (32%)                          1/30 (3%)                            4/63 (6%)                             5/93 (5%)
                                17               Lung                                Direct seq                          10 (59%)                          1/10 (10%)                           1/7 (14%)                            2/17 (12%)
  Etienne-Grimaldi      2008    48               Liver biopsy                        PCR-RFLP                            16 (33%)                            0 (0%)                               0 (0%)                               0 (0%)
  Italiano              2009    59               Not specified                       Seq                                 23 (39%)                          1/23 (4%)                            2/36 (6%)                             3/59 (5%)
  Losi                  1992    19               Local recurrence                    Multiplex-ASPCR                     12 (63%)                            0 (0%)                               0 (0%)                               0 (0%)
                                16               Metastasis, 38% liver               Multiplex-ASPCR                     13 (81%)                            0 (0%)                               0 (0%)                               0 (0%)
  Loupakis              2009    43               Liver                               Seq                               Not mentioned                         0 (0%)                               2/^\*^                              2/43 (5%)
  Molinari              2009    37               Diverse, 74% liver                  Seq                                 16 (43%)                          2/16 (13%)                           1/21 (5%)                             3/37 (8%)
                                15               Lymph node                          Seq                                  8 (53%)                            0 (0%)                               0 (0%)                               0 (0%)
  Oliveira              2006    28               Lymph node                          Not mentioned                       18 (64%)                          2/18 (11%)                           7/10 (70%)                           9/28 (32%)
  Oudejans              1991    31               Liver and lung                      Hybridization                       14 (45%)                          1/14 (7%)                            1/17 (6%)                             2/31 (6%)
  Perrone               2008    10               Diverse, mainly liver               Direct seq                           2 (20%)                          1/2 (50%)                            1/8 (13%)                            2/10 (20%)
  Santini               2008    99               Diverse, 80% liver                  Seq                                 38 (38%)                          3/38 (8%)                            1/61 (2%)                             4/99 (4%)
  Garm Spindler         2009    31               Not specified                       qPCR                                11 (35%)                          2/11 (18%)                           0/20 (0%)                             2/31 (6%)
  Suchy                 1992    58               Autopsy material, not specified     Dot-blot hybridization              15 (26%)                            0 (0%)                               0 (0%)                               0 (0%)
  Weber                 2006    36               Liver                               Seq                                 14 (39%)                            0 (0%)                               0 (0%)                               0 (0%)
  Zauber                2003    42               Diverse, 93% lymph node, 5% liver   SCCP analysis + seq                 22 (52%)                            0 (0%)                               0 (0%)                               0 (0%)
                                                                                                                                                                                                                                           
  Overall                       892              All sites                           All methods                       345/849 (41%)                      39/345 (11%)                         35/504 (7%)                           76/892 (9%)
                                276              Liver                               All methods                       84/233 (36%)                        8/84 (10%)                          11/149 (7%)                           21/276 (8%)
                                129              Lymph nodes                         All methods                       65/129 (50%)                       18/65 (28%)                          14/64 (22%)                          32/129 (25%)

Abbreviations: ASO=allele-specific oligonucleotide; ASPCR=allele-specific polymerase chain reaction; M=metastasis; pts=patients; PT=primary tumour; qPCR= quantitative PCR; RFLP=restriction fragment length polymorphism; SSCP=single strand conformational polymorphism; seq=sequencing. ^\*^Total number of cases not specified.

[^1]: These authors contributed equally to this work.
